New Protocol: TFOX for Advanced Gastric Cancer

  • Study

    Phase 3, open-label, multicenter randomized trial (PRODIGE 51- FFCD-GASTFOX)
    Pts with previously untreated advanced HER2-negative gastric/GEJ adenocarcinoma
    TFOX (docetaxel + oxaliplatin + leucovorin + 5-FU) vs. FOLFOX

  • Efficacy

    ORR: 62.3% vs. 53.4% (TFOX vs. FOLFOX)
    CR: 6% vs. 6%
    mPFS: 7.6 mos vs. 6.0 mos (p = 0.007)
    mOS: 15.1 mos vs. 12.7 mos

  • Safety

    Grade ≥3 AEs: neutropenia (27% vs. 18%), diarrhea (15% vs. 7%), neuropathy (32% vs. 20%)


    • Lancet Oncol 2025; published online Apr 23

    Zaanan A,Bouche O,de la Fouchardière C TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial

    http://doi.org/10.1016/S1470-2045(24)00545-1

    Reviewed by Ulas D. Bayraktar, MD on May 5, 2025

    Altai Oncology App
    Download Altai Oncology App On App Store
    Download Altai Oncology App On Play Store
    • Chemotherapy Protocols
    • Summarized References
    • Oncology Drug Specs
    • TNM Staging
    • BSA, CrCl Calculator
    Back to top Drag